The purchase would give Cochlear products for people with mild to moderate hearing loss, adding to ear implants for those who have lost all or most of their hearing. The acquisition would distract Sydney based Cochlear from its strategy of selling to more patients who need the implants and introducing its own products for those with less severe hearing loss, said Shane Storey , an analyst at Wilson HTM in Brisbane."It just seems they have enough growth potential within their own research pipeline," Storey said in a telephone interview. A purchase in the competitive hearing aid industry "would seem to be a step in the wrong direction," he said 
Share:  The purchase would give <span class="company">Cochlear</span> products for people with mild to moderate hearing loss, adding to ear implants for those who have lost all or most of their hearing.<span class="sent"> The acquisition would distract Sydney based <span class="company">Cochlear</span> from its strategy of selling to more patients who need the implants and introducing its own products for those with less severe hearing loss, said <span class="analyst">Shane Storey</span> , an analyst at Wilson HTM in Brisbane."It</span> just seems they have enough growth potential within their own research pipeline," Storey said in a telephone interview. A purchase in the competitive hearing aid industry "would seem to be a step in the wrong direction," he said....The purchase would give <span class="company">Cochlear</span> products for people with mild to moderate hearing loss, adding to ear implants for those who have lost all or most of their hearing.<span class="sent"> The acquisition would distract Sydney based <span class="company">Cochlear</span> from its strategy of selling to more patients who need the implants and introducing its own products for those with less severe hearing loss, said <span class="analyst">Shane Storey</span> , an analyst at Wilson HTM in Brisbane."It</span> just seems they have enough growth potential within their own research pipeline," Storey said in a telephone interview. A purchase in the competitive hearing aid industry "would seem to be a step in the wrong direction," he said. Tweet this 

The US dollar weakened 11 percent against the Australian currency in the six months and the euro lost 83 percent, compared with gains in the same period a year earlier, according to data compiled by Bloomberg Sonic fell 42 Australian cents, or 29 percent, to A$1407 as of 2:03 pm in Sydney trading, the lowest since Dec 1 The benchmark S&P/ASX 200 Index declined 05 percent ‘Waking Up' "The market is waking up to the fact that it's no longer an Australian company," said Shane Storey , an analyst at Wilson HTM Investment Group in Brisbane "The premium that it's traded at is less appropriate now that most of the earnings are coming from offshore" 
Share:  The US dollar weakened 11 percent against the Australian currency in the six months and the euro lost 83 percent, compared with gains in the same period a year earlier, according to data compiled by Bloomberg <span class="company">Sonic</span> fell 42 Australian cents, or 29 percent, to A$1407 as of 2:03 pm in Sydney trading, the lowest since Dec 1 The benchmark S&P/ASX 200 Index declined 05 percent<span class="sent"> ‘Waking Up' "The market is waking up to the fact that it's no longer an Australian company," said <span class="analyst">Shane Storey</span> , an analyst at Wilson HTM Investment Group in Brisbane</span> "The premium that it's traded at is less appropriate now that most of the earnings are coming from offshore" Tweet this 

Analysts projected A$530 million, the median of five estimates compiled by Bloomberg CSL climbed the most in eight months in Sydney Chief Executive Officer Brian McNamee said full year net income will be "towards the upper end" of CSL's forecast of between A$970 million and A$107 billion at current exchange rates The company, the world's second biggest maker of treatments derived from blood plasma, said half year earnings benefited from increased profitability of its best selling plasma products and demand in emerging markets "They'll pretty easily get to the top end of the range" on plasma product sales, Shane Storey, a health care analyst at Wilson HTM Investment Group in Brisbane, said by telephone 
Share:  Analysts projected A$530 million, the median of five estimates compiled by Bloomberg <span class="company">CSL</span> climbed the most in eight months in Sydney Chief Executive Officer Brian McNamee said full year net income will be "towards the upper end" of <span class="company">CSL</span>'s forecast of between A$970 million and A$107 billion at current exchange rates The company, the world's second biggest maker of treatments derived from blood plasma, said half year earnings benefited from increased profitability of its best selling plasma products and demand in emerging markets<span class="sent"> "They'll pretty easily get to the top end of the range" on plasma product sales, <span class="analyst">Shane Storey</span>, a health care analyst at Wilson HTM Investment Group in Brisbane, said by telephone</span>...<span class="company">CSL</span> climbed the most in eight months in Sydney Chief Executive Officer Brian McNamee said full year net income will be "towards the upper end" of <span class="company">CSL</span>'s forecast of between A$970 million and A$107 billion at current exchange rates The company, the world's second biggest maker of treatments derived from blood plasma, said half year earnings benefited from increased profitability of its best selling plasma products and demand in emerging markets<span class="sent"> "They'll pretty easily get to the top end of the range" on plasma product sales, <span class="analyst">Shane Storey</span>, a health care analyst at Wilson HTM Investment Gr Tweet this 

An FDA advisory panel will review the findings and make recommendations on approval Feb 10 Omapro would be the first treatment for chronic myeloid leukemia patients with the T315I genetic mutation that makes them resistant to existing treatments including Novartis AG's Gleevec Sales of treatments for drug resistant chronic myeloid leukemia may reach $380 million by 2020, according to Shane Storey , an analyst with Wilson HTM Investment Group in Brisbane In the study reviewed by the FDA, data were submitted from only 66 of the 100 patients who planned to enroll, and 15 percent of patients responded to chronic treatment The average benefit was 77 months 
Share:  An FDA advisory panel will review the findings and make recommendations on approval Feb 10 Omapro would be the first treatment for chronic myeloid leukemia patients with the T315I genetic mutation that makes them resistant to existing treatments including <span class="company">Novartis AG</span>'s Gleevec<span class="sent"> Sales of treatments for drug resistant chronic myeloid leukemia may reach $380 million by 2020, according to <span class="analyst">Shane Storey</span> , an analyst with Wilson HTM Investment Group in Brisbane</span> In the study reviewed by the FDA, data were submitted from only 66 of the 100 patients who planned to enroll, and 15 percent of patients responded to chronic treatment The average benefit was 77 months Tweet this 

An FDA advisory panel will review the staff findings and make recommendations on approval Feb 10 Omapro works differently from to Novartis AG's Gleevec and Tasigna and Bristol Myers Squibb Co 's Sprycel, and would be the first treatment for patients with the so called T315I mutation that causes resistance to those drugs Sales of treatments for drug resistant chronic myeloid leukemia may reach $380 million by 2020, said Shane Storey , an analyst with Wilson HTM Investment Group in Brisbane "If this product is approved, then there is a new option for at home administration of something that's going to give patients a durable response," Storey said by phone before the FDA report was posted "It's preferable to the aggressive chemotherapy options that CML patients have once they've developed T315I and face accelerated disease" 
Share:  An FDA advisory panel will review the staff findings and make recommendations on approval Feb 10 Omapro works differently from to <span class="company">Novartis AG</span>'s Gleevec and Tasigna and Bristol Myers Squibb Co 's Sprycel, and would be the first treatment for patients with the so called T315I mutation that causes resistance to those drugs<span class="sent"> Sales of treatments for drug resistant chronic myeloid leukemia may reach $380 million by 2020, said <span class="analyst">Shane Storey</span> , an analyst with Wilson HTM Investment Group in Brisbane</span> "If this product is approved, then there is a new option for at home administration of something that's going to give patients a durable response," Storey said by phone before the FDA report was posted "It's preferable to the aggressive chemotherapy options that CML patients have once they've developed T315I and face accelerated disease" Tweet this 

While the company has a stranglehold on the implants market , with 70 per cent market share , it has little experience with hearing aids aimed at those with less severe hearing loss While acquiring the Siemens business would give Cochlear a 25 per cent global market share, Cochlear has not flagged an intention to expand into the hearing aid market The strategic fit is not immediately obvious and some analysts question the synergistic benefits arising from the deal ''You tend to think hearing aids are a pretty mature market I can't see why they [Cochlear] would bother,'' said Wilson HTM senior research analyst Shane Storey 
Share:  While the company has a stranglehold on the implants market , with 70 per cent market share , it has little experience with hearing aids aimed at those with less severe hearing loss While acquiring the <span class="company">Siemens</span> business would give Cochlear a 25 per cent global market share, Cochlear has not flagged an intention to expand into the hearing aid market The strategic fit is not immediately obvious and some analysts question the synergistic benefits arising from the deal<span class="sent"> ''You tend to think hearing aids are a pretty mature market I can't see why they [Cochlear] would bother,'' said Wilson HTM senior research analyst <span class="analyst">Shane Storey</span></span> Tweet this 

The market for patients who fail two or more drugs in Gleevec's category may reach $1.4 billion by 2020, according to Shane Storey, a healthcare analyst with Wilson HTM Investment Group in Brisbane.  
Share:  <span class="sent">The market for patients who fail two or more drugs in <span class="company">Gleevec</span>'s category may reach $1.4 billion by 2020, according to <span class="analyst">Shane Storey</span>, a healthcare analyst with Wilson HTM Investment Group in Brisbane. </span> Tweet this 

The market for patients who fail two or more drugs in Gleevec's category may reach $1.4 billion by 2020, according to Shane Storey, a health care analyst with Wilson HTM Investment Group in Brisbane.  
Share:  <span class="sent">The market for patients who fail two or more drugs in <span class="company">Gleevec</span>'s category may reach $1.4 billion by 2020, according to <span class="analyst">Shane Storey</span>, a health care analyst with Wilson HTM Investment Group in Brisbane. </span> Tweet this 

About half of all CML patients develop resistance to Gleevec over five years, studies have shown. The market for patients who fail two or more TKIs may reach $1.4 billion by 2020, according to Shane Storey , a health care analyst at Wilson HTM Investment Group in Brisbane. "It may even be larger than that," Storey said by phone yesterday, before the results were announced. "It seems that people who go onto their third TKI don't get a durable response. 
Share:  About half of all CML patients develop resistance to <span class="company">Gleevec</span> over five years, studies have shown. <span class="sent"> The market for patients who fail two or more TKIs may reach $1.4 billion by 2020, according to <span class="analyst">Shane Storey</span> , a health care analyst at Wilson HTM Investment Group in Brisbane. </span> "It may even be larger than that," Storey said by phone yesterday, before the results were announced. "It seems that people who go onto their third TKI don't get a durable response. Tweet this 

Global sales of treatments for the drug resistant form of the disease may reach $500 million by 2020, said Shane Storey , a biotechnology analyst with Wilson HTM in Brisbane, in a report last month. ChemGenex shares have gained 20 percent this year, compared with a 6.3 percent gain in the All Ordinaries Index of Australia's largest 497 companies by market value. Chronic myeloid leukemia , or CML, is a slow progressing disease in which a genetic flaw triggers a person's bone marrow to produce too many white blood cells, which don't mature and aren't able to perform their normal infection fighting role. About 4,830 people were diagnosed with the disease in the U.S. last year, with a median age of 67, according to the National Cancer Institute. Yew Trees Omacetaxine is derived from the yew tree known as Cephalotaxus harringtonia. 
Share:  <span class="sent">Global sales of treatments for the drug resistant form of the disease may reach $500 million by 2020, said <span class="analyst">Shane Storey</span> , a biotechnology analyst with Wilson HTM in Brisbane, in a report last month. </span> <span class="company">ChemGenex</span> shares have gained 20 percent this year, compared with a 6.3 percent gain in the All Ordinaries Index of Australia's largest 497 companies by market value. Chronic myeloid leukemia , or CML, is a slow progressing disease in which a genetic flaw triggers a person's bone marrow to produce too many white blood cells, which don't mature and aren't able to perform their normal infection fighting role. About 4,830 people were diagnosed with the disease in the U.S. last year, with a median age of 67, according to the National Cancer Institute. Yew Trees Omacetaxine is derived from the yew tree known as Cephalotaxus harringtonia. Tweet this